People who experience intense grief and prolonged yearning tend to have higher oxytocin receptor density in the nucleus accumbens, the brain's motivation and craving center.
Snapshot · Huberman Lab
People who experience intense grief and prolonged yearning tend to have higher oxytocin receptor density in the nucleus accumbens, the brain's motivation and craving center.
Where this was said
At 23:10 · chapter starts 22:30
Huberman breaks for the second sponsor segment, promoting LMNT, an electrolyte drink containing sodium, magnesium, and potassium without sugar. He explains the physiological rationale: even mild dehydration degrades cognitive and physical performance, and adequate electrolytes are essential for all cellular function, especially in neurons. Huberman describes dissolving one LMNT packet in 16 to 32 ounces of water first thing in the morning and during exercise, particularly on hot days. He highlights current flavors including raspberry, citrus, and a limited-edition lemonade, and directs listeners to drinklmnt.com/huberman for a free sample pack with any purchase.
A study in Biological Psychology tested whether writing about a lost loved one would help bereaved individuals heal — and found no overall effect. The twist: people with high vagal tone, who can strongly modulate heart rate through breathing, did benefit significantly. The ability to physically feel your emotions is what makes grief work work.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.